News
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE: JNJ) stock has largely tread water over the last few months. Wouldn't it be nice if the healthcare giant had a catalyst or....
Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?
Historically, 99% of Alzheimer's disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer's disease drug,....
3 Biotech Stocks With Major Catalysts in October
Every month brings plenty of catalysts for several biotech stocks. October is no exception. There are quite a few regulatory decisions and clinical results expected to be announced next....
The Creative Ways Drugmakers Are Delaying Generics
Drugmakers are increasingly embracing new tactics to protect billions of dollars in sales from generic competition. These strategies often involve patent trials, but that's not the only way....
3 Reasons to Buy the Dip With Exelixis
In just two days, Exelixis (NASDAQ: EXEL) has lost over 15% of its market cap. The tumble for the once-hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink....
Caveat Emptor When Buying High-Yield Drug Stocks
Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend. The telecom and utility sectors often generate some of the most robust payouts for investors, with....
5 Numbers That Should Get MannKind Investors Excited
MannKind (NASDAQ: MNKD) hasn't exactly given investors a whole lot to get excited about in recent years. That could be changing, though. Since May, MannKind stock has soared more than 130% and now....
3 Bargain Biotech Stocks You Can Buy Today
You might have heard that the stock market is overpriced after years of solid gains. And it is. That doesn't mean every stock is overpriced, though.Actually, several biotech stocks look....
3 Warren Buffett Stocks for Retirees
Warren Buffett is arguably the most revered investor on the planet. Over the course of more than six decades he's turned less than $10,000 into a net worth of nearly $79 billion. What's truly....
12 Flu Season Facts You Need to Know
Fall is officially here, and that usually means three things: pumpkin-spiced everything is back in style, our lush trees are about to become leafless sticks, and that sniffle and cough could be....
7 Reasons Your Obamacare Premium Could Soar by a Double-Digit Percentage in 2018
In just over five weeks, open enrollment for the Affordable Care Act (ACA), which is best known as Obamacare, will begin. The upcoming enrollment period could very well rival the first enrollment....
AbbVie's Unfazed by the Risk of Generic Humira
Over 60% of AbbVie Inc.’s (NYSE: ABBV) sales come from demand for Humira -- an autoimmune-disease drug prescribed to patients with a variety of conditions -- that racks up sales of $16 billion per....
Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
If you had the misfortune to buy Novavax (NASDAQ: NVAX) stock in July 2015 and held on, around 90% of your investment would have been wiped out. Ouch. Even if you had bought the biotech stock at....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
One great thing about the biotech industry is that there are nearly always some winners. Regardless of what's going on in the world or in the broader market, at least a few biotech stocks are....
Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson
There aren't many companies that can grow sales and profits through a wide range of market conditions. But both Kimberly-Clark (NYSE: KMB), the consumer goods specialist, and Johnson & Johnson....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4%
Shares of biopharma Versartis (NASDAQ: VSAR) crashed nearly 87% Friday after somavaratan, the company's lead drug candidate, did not meet its primary endpoint in the phase 3 Velocity trial. The....
AstraZeneca Stock Upgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Last week, Gilead Sciences (NASDAQ: GILD) announced that it was borrowing $3 billion. That's billion with a "B."The company doesn't really need the money. It was sitting on $36.6 billion in cash,....
3 Big Biotech Stocks to Buy This Fall
A change in season presents a good time to look for great stocks to buy. And one of the best places to look is in the biotech industry. Biotech stocks in general are trouncing the S&P 500....
These 3 Stocks Are Priced for Perfection. Can They Deliver?
You expect a top-ranked football team to play well every game. You expect the Kentucky Derby winner to place in the Preakness Stakes. And you expect a stock with a high valuation to generate....
Better Buy: Celgene Corporation vs. Merck & Co., Inc.
Based on recent history, Celgene Corporation (NASDAQ: CELG) and Merck & Co. (NYSE: MRK) stocks don't even belong in the same league. Celgene stock is up more than 270% over the past five....
3 Biotech Stocks With Major Catalysts Incoming
Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc. (NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences,....
3 Stocks to Help You Make Money in Retirement
Especially if you're looking forward to a long retirement, you'll still want to own some stocks after you've cashed your final paycheck. Unlike cash or many bonds these days, returns from stocks....
3 Small-Cap Biotech Stocks to Buy This Fall
Hundreds of small-cap biotech stocks are available for investors. All of them come with relatively high levels of risk. With that high risk, though, also comes the potential for high returns.But....